Selective calcium channel antagonists
AssigneeNorthwestern University
InventorsDalton J. Surmeier, Jr., Richard B. Silverman, Soosung Kang, Garry Cooper
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.
Claims12
A method of selectively inhibiting a Cav1.3-calcium ion channel, comprising contacting said Cav1.3-calcium ion channel with a compound of the formula:
- wherein R1 is cyclopentane or cyclohexane, and R2 is a meta-substituted phenethyl group, wherein the compound is a selective Cav1.3-calcium ion channel inhibitor.
A method of treating a neurodegenerative disorder comprising administering to a subject a Cav1.3-selective calcium ion channel antagonist of the formula:
- wherein R1 is cyclopentane or cyclohexane, and R2 is a meta-substituted phenethyl group, wherein the compound is a selective Cav1.3-calcium ion channel inhibitor, and wherein treating is not preventing.
Dependencies are inferred from the claim text.